Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20-19 Tan BB06z CAR T in Relapsed/Refractory CD19+ Hematologic Malignancies
NCT07701889Phase 1Not yet recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hematologic malignancy, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 2 years. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07701889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701889.